DOTmed February 14, 2025
Novartis has agreed to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company focused on cardiovascular and thrombotic diseases, in a deal valued at up to $3.1 billion.
The acquisition will bring abelacimab, Anthos’ investigational Factor XI inhibitor, back under Novartis’ control.
Anthos was founded in 2019 by Blackstone Life Sciences and Novartis, with exclusive global rights to develop and commercialize abelacimab. The drug is being investigated for stroke prevention in patients with atrial fibrillation and for reducing recurrent blood clots in patients with cancer.
“Abelacimab has the potential to be an important treatment option for the millions of patients globally with atrial fibrillation at high risk of stroke, and we could not have more conviction in the potential of this asset,”...
Today's Sponsors
Today's Sponsor